黑色素瘤 TIL（肿瘤浸润淋巴细胞）治疗的最新进展

Recent Advances in Tumor-Infiltrating Lymphocyte Therapy for Melanoma.

免疫细胞因子特征可预测接受溶瘤腺病毒 TILT-123 联合化疗及无 IL-2 过继性 TIL 治疗的晚期黑色素瘤患者的生存

Immune-cytokine signature predicts survival in patients with advanced melanoma treated with oncolytic adenovirus TILT-123 and chemotherapy and IL-2-fr

这些发现为 TILT-123 联合 TIL 疗法提供了机制上的见解，并为未来的生物标志物导向临床研究提出了方向。

利用树突状细胞（DCs）进行黑色素瘤免疫治疗：从基础生物学到临床策略

Harnessing dendritic cells (DCs) for melanoma immunotherapy: From basic biology to clinical strategies.

EGFRxCD16 双特异性抗体联合溶瘤病毒驱动 NK 细胞介导的卵巢癌与 NSCLC 细胞系高效裂解

EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic virus

从切除到免疫：现代黑色素瘤治疗的全谱系

From Excision to Immunity: The Full Spectrum of Modern Melanoma Treatments.

溶瘤病毒治疗抵消免疫治疗后 IFN 无应答癌细胞的选择，但受限于去分化癌细胞的出现

Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiate

转移性葡萄膜黑色素瘤治疗方式的疗效比较：一项系统评价和网络 meta 分析

Comparative efficacy of therapeutic modalities for metastatic uveal melanoma: a systemic review and network meta-analysis.

基于现有数据，在转移性葡萄膜黑色素瘤中，与 Tebentafusp、ICIs 及其他治疗方式相比，肝脏导向治疗联合 ICIs 在延长 OS 和 PFS 方面取得了最佳结果。有必要开展纳入新兴疗法的未来对比研究。

瘤内注射常规树突状细胞重振肿瘤-免疫循环治疗黑色素瘤及其他实体瘤：叙述性综述

Reinvigorating the Cancer-Immunity Cycle by Intratumoral Administration of Conventional Dendritic Cells in Melanoma and Other Solid Tumors: A Narrativ

检查点抑制及其超越：针对眼部恶性肿瘤免疫豁免格局的精准免疫工程

Checkpoint inhibition and beyond: Precision immune engineering for the immune-privileged landscape of ocular malignancies.

溶瘤人疱疹病毒用于癌症治疗

Oncolytic human herpesvirus for cancer therapy.